Failed again: Sanofi's Abl­ynx re­ports PhII lu­pus flop

Af­ter los­ing its high-pro­file rheuma­toid arthri­tis part­ner­ship just two years ear­li­er, Sanofi’s Bel­gium-based biotech Abl­ynx could once again put an Ab­b­Vie pact on the chop­ping block af­ter post­ing a Phase II flop this morn­ing.

Abl­ynx re­port­ed out bad news that vo­bar­il­izum­ab dis­ap­point­ed yet again, fail­ing to meet its pri­ma­ry end­points in a Phase II lu­pus study. It’s the same drug that fiz­zled in RA, which Ab­b­Vie punt­ed back in 2016.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Venture & Research Associate

Alexandria Real Estate Equities

San Francisco, CA, USA